The apical membrane Na + /H + antiporter isoforms, NHE-2 and NHE-3, are involved in transepithelial Na + absorption in the intestine. However, they exhibit differences in their pattern of tissue expression and regulation of their activity by various molecular signals. To study the mechanisms involved in transcriptional regulation of these genes, we characterized cis-acting elements within the human NHE2 promoter that regulate the NHE2 promoter expression in C2/bbe cells. A small DNA region (-85/+249) is involved in regulation of the basal transcriptional activity of the NHE-2 promoter as determined by transient transfection assays.
INTRODUCTION
$ASQG-00010-2005.R1_1 Figure 1A , the NHE2 mRNA expression increased with time after PMA treatment reaching a maximum level after 6 h and returned to the baseline by 24 h. To examine the mechanism by which PMA treatment leads to increased NHE2 mRNA expression, we pre-treated the C2/bbe cells with the transcription inhibitor actinomycin D or protein synthesis inhibitor cycloheximide, the cells were then incubated in presence or absence of PMA and subsequently RT-PCR analysis was performed. As shown in Figure 1B , lanes 4 and 7, simultaneous presence of the actinomycin D and PMA did not result in enhanced NHE2 mRNA levels, suggesting that the stability of the NHE2 mRNA was not prolonged. Cycloheximide treatment blocked the PMAinduced increase in NHE2 mRNA as well (Fig. 1B, lane 11) . Therefore, these observations indicate that the up-regulation of the human NHE2 mRNA expression by PMA is mediated at the transcriptional level and requires de novo protein synthesis.
Identification of the PMA-response region within the human NHE2 promoter. We next examined the effect of PMA treatment on the transcriptional regulation of the NHE2 promoter. C2/bbe cells were transiently transfected with the 5'-truncated NHE2 promoterreporter constructs and cultivated in serum starvation media for at least 24 hours. The cells were then treated with 100 nM PMA or the vehicle for 16 h, harvested and lysed. Luciferase activity was measured in the cell lysates of PMA treated and untreated cells. PMA treatment resulted in a 2-3 fold increase in luciferase activity of the p-861/+249 compared to the control ( Fig. 2A ), indicating that a PMA responsive element(s) was located in this promoter fragment. p-415/+249, also responded to PMA with a 2-3 fold increase in luciferase activity. The promoer-repoter constructs containing the sequences from bp -296 to +249 also displayed a minor increase (10-20%) in luciferase activity in response to PMA. These data indicated that the cis-element(s) responsible for PMA-effect were located on the DNA region downstream from position -415.
The nucleotide sequences of the promoter region downstream from bp -415 were scanned by MatInspector application (http://www.genomatix.de) to identify the potential transcription binding sites. Two overlapping Sp1/Egr-1 motifs were detected (Fig. 2B) .
Sequences similar to region containing the overlapping Sp1/Egr-1 motifs have been shown to be the target of PMA-response factors in different systems (11, 12, 23, 24, 46, 51) . Consistent with our functional analysis ( Fig. 2A) , the potential distal PMA-response element (D-PRE) containing the overlapping Sp1/Egr-1 motif is located at bp -339 to -324. This element is composed of two Egr-1 binding sites that overlap by three nucleotides, and an Sp1 consensus sequence that overlaps with both of the Egr-1 binding sites (Fig. 2B) . The putative proximal PMA-response element (P-PRE) is situated at the bp -32 to -19 and contains three potential overlapping Sp1 sites of which the 3' element also overlaps with an Egr-1 binding site (Fig.2B) . The overlapping configuration of these elements suggests that the binding of each transcription factor can be mutually exclusive.
PMA Treatment induces the Egr-1 mRNA and protein expression in C2/bbe cells. The sequences of both the distal and proximal PMA-response elements in the promoter region of the hNHE2 gene are highly homologous to motifs identified in the promoter region of other genes, which are a target of PMA-induced transcription factor Egr-1. To explore the possibility that the NHE2 gene may also be regulated by Egr-1, we examined the kinetics of the Egr-1 mRNA and protein expression in response to PMA treatment in C2/bbe cells. As shown in Figure 3A , Egr-1 mRNA level was increased dramatically by 1 hr post PMA treatment and the elevated level of mRNA expression persisted for up-to 4 h and returned to the basal levels by 16 h after PMA treatment. Egr-1 protein abundance in C2/bbe nuclear extracts also increased in response to PMA treatment and was maximal by 2 h after exposure to PMA. The elevated levels of Egr-1 protein reduced to the basal level by 16 h after PMA treatment, as determined by Western blot analysis ( Fig. 3B ) and compared to the tubulin protein expression.
Transcription factors Sp1, Sp3 and Egr-1 interact with the distal and proximal PREs of the human NHE2 promoter. The results of functional analysis of the 5'-deletion constructs ( Fig. 2A ) implicated the distal PRE as the major site involved in PMA responsiveness of the hNHE2 promoter. Therefore, we have focused our further studies to characterize this motif in more detail. To identify the specific nuclear factors that may interact with the distal PMAresponse element, we used a double-stranded oligonucleotide probe corresponding to bp -345 to -319 and nuclear proteins from untreated and PMA-treated cells in gel mobility shift assays.
This probe harbors the potential D-PRE. When incubated with the nuclear extracts from cells grown under basal growth conditions (DMEM+10% FBS), four DNA/protein complexes were (C1-C4) formed with this probe (Fig. 4A , lane 1). The binding specificity of complexes was determined by competition assays, where all complexes were removed when unlabeled probe was used as a competitor and a non-specific unlabeled oligonucleotide did not compete with any of the complexes (data not shown). Since the distal PMA-response element contained a potential binding site for Sp1, we examined whether any of the detected DNA/protein complexes were related to Sp1. For this purpose, an excess of unlabeled oligonucleotide containing the Sp1 consensus binding sequence was utilized as a competitor (Fig.4A, lane 2) . This oligonucleotide eliminated all complexes except for C3 and a diffused smeary band migrating under C3, suggesting that the Sp1 family members interact with this DNA region.
To identify the protein components of these complexes, supershift experiments were performed using anti-Sp1, Sp3 and Egr-1 antibodies (Fig. 4A , lanes 3-5, respectively).
Incubation of nuclear extracts with Sp1 antibody completely blocked formation of the C1 and identified the protein present in C1, as Sp1; anti-Sp3 antibody removed the C2 and the fastest migrating complex C4, therefore, identifying the protein component of the C2 and C4 as Sp3; antibody to Sp2 failed to generate a supershift or to eliminate any of the complexes (data not shown); a faint and diffused band that migrates under C3 (lane 2) was removed with anti-Egr-1 antibody, thus suggesting that this broad band may represent the Egr-1 transcription factor (also see Fig. 4C, lanes 2 and 3) . The identity of the protein in C3 is not known at this time and is designated, NF-X. Therefore we conclude that in the constitutive basal conditions the Sp1, Sp3, an unknown nuclear factor (NF-X) and low levels of Egr-1 are the proteins that interact with the distal PMA-response element.
To assess whether PMA treatment leads to differential interactions of nuclear factors with the D-PRE, nuclear proteins from PMA treated cells were utilized in GMSA. As shown in Figure 4B , a single DNA/protein complex was detected. This PMA-induced DNA binding protein was identified as Egr-1 by supershift experiments with anti-Egr-1 antibody (Fig. 4B, lane   5 and Fig. 4C, lane 5) . Supershift analysis using anti-Sp1, -Sp2 and -Sp3 did not affect DNA/protein complex formation (Fig. 4B, lanes 2-4) . Therefore, it appears that binding of PMA-induced Egr-1 to this region interferes with binding of the Sp family members with the D-PRE motif.
As a part of another study we have previously shown that transcription factors Sp1 and Sp3 bind to NHE2 promoter region from bp -37 to -14 at the basal growth conditions (Malakooti, Ramaswamy unpublished data). This region contains the P-PRE. To confirm whether the same proteins interact with both the distal-and proximal PMA-response elements, competition experiments were performed with the end-labeled probe containing the D-PRE and unlabeled oligonucleotides harboring the D-PRE (Fig. 4D, lane 2) or P-PRE (Fig. 4D, lane 4) of increase for PMA-induced reporter activity was comparable in mutant M1 and M2 (2.4 and 2.1, respectively), and M3 mutant exhibited a 1.3-fold increase in response to PMA. Our results showing that M3 mutation did not completely suppress PMA-induced reporter gene activity support the results of Figure 4 that the P-PRE is also involved in PMA-response, albeit to a much lesser extent. These data suggest that PMA-induced Egr-1 protein binding to either 5' or 3' binding sites may compensate to some extent for the lack of interactions with the other response element. A drastic decrease in the luciferase activity with M3 mutation suggests that binding of Egr-1 to these sites is necessary for maximal activation of the human NHE2 promoter in basal and stimulated conditions. Egr-1 over-expression induces NHE2 promoter-reporter gene expression. To establish the transactivational importance of the Egr-1 transcription factor for regulation of the NHE2 gene expression, we co-transfected the p-415/+249 NHE2 promoter-reporter construct with a human Egr-1 expression vector or a control empty vector into C2/bbe cells. Indeed, as shown in Figure   8B , co-transfection of the Egr-1 expression vector led to a 2-fold increase in luciferase activity, compared to mock co-transfected cells that showed no increase in reporter activity. These studies demonstrated that the expression of Egr-1 alone is sufficient to stimulate NHE2 promoter activity in C2/bbe cells. However, when Egr-1 co-transfected cells were treated with PMA, the luciferase activity in response to simultaneous over-expression of Egr-1 and addition of PMA did not show a significant synergistic effect. This may suggest that the overexpressed level of Egr-1 in transfected cells is sufficient to transactivate the NHE2 promoter but not to the level of stimulation by PMA. of 100 nM PMA. Lane 2 and 6 were treated with PMA only for 2 and 6 h, respectively. Lanes 1 and 8 represent the untreated cells. In lanes 10 and 11, C2/bbe cells were pre-incubated with 15 µg/ml cycloheximide for 60 min and then treated with 100 nM PMA for 6 h in the presence of the inhibitor (lane 11). Lane 9 represents cells grown in presence of PMA for 6 h. min incubation at room temperature resolved on a 5% non-denaturing polyacrylamide gels. A total of 2 µg DNA was use for each transfection. pSV-ßgal was used as an internal control for transfection efficiency in all experiments. All transfections were done in triplicates and repeated at least three times. Data from one representative experiment are shown.
